Transgene

Beleggen in aandelen beurzen Frankfurt DAX, Londen FTSE 100, Parijs CAC40, etc.
Plaats reactie
Stofke
Forum actieveling
Forum actieveling
Berichten: 328
Lid geworden op: 13 Okt 2017 16:18
waarderingen: 205
Contact:

Re: Transgene

Berichtdoor Stofke » 28 Jun 2018 09:38

Bioscience schreef:VANDAAG // June 27, 2018 - Spring Midcap Event: June 27 & 28, 2018 – Paris, France

https://www.transgene.fr/wp-content/upl ... h_2018.pdf
Wordt wel tijd voor een nieuwe corporate presentation . Na maart is er veel positief nieuws bijgeschreven

Ze mogen daar wel wat hun best gaan doen . Voorlopig zeer tegenvallende koers voor een veelbelovend bedrijf . Hoogste koers 12,64 / febr. 2014


Vind ik persoonlijk ook, als Apitope op de markt komt ga ik hier hopelijk met winst wat verkopen. Zit al zo lang op die Apitope te wachten. Hoop toch dit jaar een beursnotering.
lode78 liked last!



Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Transgene

Berichtdoor Munnybunny » 28 Jun 2018 12:30

Interessant genoeg om in te stappen. So I am in. Dit heeft mij getriggerd "On track to deliver multiple value-enhancing clinical data readouts and preclinical milestones".
lode78 liked last!

Brammeke
Forum actieveling
Forum actieveling
Berichten: 599
Lid geworden op: 19 Okt 2016 15:33
waarderingen: 179
Contact:

Re: Transgene

Berichtdoor Brammeke » 29 Jun 2018 19:25

bijgekocht aan 2,99.
gemiddeld: 3,017.
lode78 liked last!

Brammeke
Forum actieveling
Forum actieveling
Berichten: 599
Lid geworden op: 19 Okt 2016 15:33
waarderingen: 179
Contact:

Re: Transgene

Berichtdoor Brammeke » 02 Jul 2018 11:18

Nog wat ingeslagen aan 2,93.
gem: 2,982.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Transgene

Berichtdoor Munnybunny » 10 Jul 2018 13:06

Spike up! Woohoo!

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Transgene

Berichtdoor Munnybunny » 10 Jul 2018 13:14

Transgene and Tasly Biopharmaceuticals Conclude Strategic Agreements for the Rights of Transgene’s Virus-Based Immunotherapies TG6002 and TG1050 in Greater China
Transgene to receive $48 million paid in newly created Tasly Biopharmaceuticals shares
Deals give Tasly Biopharmaceuticals full control over Greater China1 development and commercial rights to the oncolytic virus T601 2 and the therapeutic vaccine T101 2
Development of these immunotherapies for the Chinese market will benefit from the significant resources and capabilities of Tasly Biopharmaceuticals
July 10, 2018 07:00 AM Eastern Daylight Time
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of Transgene’s virus-based immunotherapies TG6002 and TG1050 in Greater China
Tweet this
Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, signed a series of agreements with Tasly Biopharmaceuticals Co., Ltd. (“Tasly Biopharmaceuticals”) involving T601 and T101, two immunotherapeutics developed by the Transgene-Tasly joint venture 3 in China. These products incorporate Transgene’s TG6002 and TG1050 technologies, respectively. As a result of these agreements Transgene will receive shares in Tasly Biopharmaceuticals valued at $48 million. These agreements are designed to further deliver the potential of Transgene’s virus-based technologies in China.

Philippe Archinard, Chairman and Chief Executive Officer of Transgene, added: “We are delighted to have signed these strategic agreements that create value for Transgene through our share ownership in Tasly Biopharmaceuticals and demonstrate the significant potential of the oncolytic virus T601 and therapeutic vaccine T101 in China. As a long-standing partner of the Tasly group, Transgene will remain involved in the further development of these products in China. We look forward to the first readout of the ongoing Phase 1 trial evaluating T101 against chronic hepatitis B, which is expected early 2019. In addition, a Phase 1 trial with the oncolytic virus T601 in China is actively being prepared.”

Kaijin Yan, Holding Group Executive Chairman of the Board of Tasly Pharmaceuticals, commented: “Our mission is to become a world-leading biotechnology company, dedicated to continuously offer high-quality and affordable drugs to patients. These new strategic agreements with Transgene provide us with the full development and commercial rights to T601 (through 100% ownership of the joint venture) and T101 in Greater China and will allow us to build a broad innovative product portfolio. We are very happy to welcome Transgene as a key supportive shareholder of Tasly Biopharmaceuticals.”

Structure of the transactions
Transgene is transferring its 50% share of the current Transgene-Tasly joint venture (Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd.) to Tasly Biopharmaceuticals, making it the 100% owner of the joint venture entity and the greater China patent rights to T601.
In parallel, Transgene is assigning the T101 patent rights in Greater China, to which the joint venture held an option, directly to Tasly Biopharmaceuticals.
As a result of these transactions, which are subject to customary closing conditions including completion of the administrative transfer of the assets contributed by Transgene to Tasly Biopharmaceuticals, Tasly Biopharmaceuticals will control all research, development and commercial rights to T601 and T101 in Greater China. In return, Transgene is receiving an aggregate of $48 million in newly created Tasly Biopharmaceuticals shares, representing 2.53% of the Tasly Biopharmaceuticals capital post completion of the Tasly Biopharmaceuticals’s pre-IPO investment round which priced simultaneously with Transgene’s transactions. Tasly Biopharmaceuticals has announced its intention to list its shares on the Hong Kong Stock Exchange.

Lazard and the Adamas law firm advised Transgene on the transaction.

A conference call in English is scheduled on July 10th at 4:00 p.m. CET.
Bioscience liked last!

Biscuitpower
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 06 Jan 2018 21:22
waarderingen: 18
Contact:

Re: Transgene

Berichtdoor Biscuitpower » 10 Jul 2018 16:52

Hupsakee +9%.

Munnybunny
Forum veteraan
Forum veteraan
Berichten: 1007
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 434
Contact:

Re: Transgene

Berichtdoor Munnybunny » 13 Jul 2018 17:16

Blijft redelijk goed liggen wachtend op meer nieuws.

Biscuitpower
Forum verkenner
Forum verkenner
Berichten: 37
Lid geworden op: 06 Jan 2018 21:22
waarderingen: 18
Contact:

Re: Transgene

Berichtdoor Biscuitpower » 13 Jul 2018 18:24

Bioscience schreef:VANDAAG // June 27, 2018 - Spring Midcap Event: June 27 & 28, 2018 – Paris, France

https://www.transgene.fr/wp-content/upl ... h_2018.pdf
Wordt wel tijd voor een nieuwe corporate presentation . Na maart is er veel positief nieuws bijgeschreven

Ze mogen daar wel wat hun best gaan doen . Voorlopig zeer tegenvallende koers voor een veelbelovend bedrijf . Hoogste koers 12,64 / febr. 2014


Nieuwe pdf op hun website (editie juli):
https://www.transgene.fr/wp-content/upl ... y-2018.pdf
Stofke liked last!

Bioscience
Forum veteraan
Forum veteraan
Berichten: 1770
Lid geworden op: 27 Jan 2015 12:11
waarderingen: 949
Contact:

Re: Transgene

Berichtdoor Bioscience » 16 Jul 2018 09:53

Thanks Bisquitpower .

Afgelopen weekend corporate presentation doorgelezen . Ziet er veelbelovend uit . Zou zo maar eens een nieuwe Argen-X in de dop kunnen zijn voor het komende jaar(en)
lode78 liked last!